Skip to main content
Erschienen in: World Journal of Urology 4/2013

01.08.2013 | Original Article

Clinical significance of preoperative peripheral blood neutrophil count in patients with non-metastatic upper urinary tract carcinoma

verfasst von: Takeshi Hashimoto, Yoshio Ohno, Jun Nakashima, Tatsuo Gondo, Makoto Ohori, Masaaki Tachibana

Erschienen in: World Journal of Urology | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Preoperative elevation of markers of systemic inflammation is associated with a poor outcome in several cancers. The purpose of this study was to evaluate the prognostic significance of preoperative systemic inflammatory markers in patients with non-metastatic upper urinary tract cancer (UUTC).

Methods

The records of 84 patients with non-metastatic UUTC who had undergone nephroureterectomy were reviewed, and the associations between preoperative clinical variables and recurrence-free survival (RFS) were analyzed by univariate and multivariate analyses.

Results

Clinical tumor stage, neutrophil count, and neutrophil-to-lymphocyte ratio were significantly associated with RFS in univariate analysis. Multivariate analysis showed that clinical T stage (hazard ratio [HR], 3.009; 95 % confidence interval [CI], 1.149–9.321; p = 0.024) and neutrophil count (HR, 3.521; 95 % CI, 1.423–9.108; p = 0.007) were independent predictors of RFS. The 3-year RFS in patients with a neutrophil count <4,000/μL was significantly higher than that in patients with a neutrophil count ≥4,000/μL (82.9 vs. 51.0 %, p = 0.004). Based on clinical T stage (T2 or less vs. T3 or greater) and neutrophil count (<4,000 vs. ≥4,000/μL), patients were stratified into 3 groups: low, intermediate, and high risk groups. RFS rates were significantly different between the 3 groups (p = 0.0005).

Conclusions

Preoperative neutrophil count was an independent predictor of RFS in patients with non-metastatic UUTC. Stratification of patients based on neutrophil count and clinical T stage may be valuable for preoperative patient counseling and identifying patients with poor prognosis who may be candidates for neoadjuvant chemotherapy.
Literatur
1.
Zurück zum Zitat Brown GA, Matin SF, Busby JE, Dinney CP, Grossman HB, Pettaway CA, Munsell MF, Kamat AM (2007) Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy. Urology 70:252–256PubMedCrossRef Brown GA, Matin SF, Busby JE, Dinney CP, Grossman HB, Pettaway CA, Munsell MF, Kamat AM (2007) Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy. Urology 70:252–256PubMedCrossRef
2.
Zurück zum Zitat Brien JC, Shariat SF, Herman MP, Ng CK, Scherr DS, Scoll B, Uzzo RG, Wille M, Eggener SE, Terrell JD, Lucas SM, Lotan Y, Boorjian SA, Raman JD (2010) Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J Urol 184:69–73PubMedCrossRef Brien JC, Shariat SF, Herman MP, Ng CK, Scherr DS, Scoll B, Uzzo RG, Wille M, Eggener SE, Terrell JD, Lucas SM, Lotan Y, Boorjian SA, Raman JD (2010) Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J Urol 184:69–73PubMedCrossRef
3.
Zurück zum Zitat Igawa M, Urakami S, Shiina H, Kishi H, Himeno Y, Ishibe T, Kadena H, Usui T (1995) Neoadjuvant chemotherapy for locally advanced urothelial cancer of the upper urinary tract. Urol Int 55:74–77PubMedCrossRef Igawa M, Urakami S, Shiina H, Kishi H, Himeno Y, Ishibe T, Kadena H, Usui T (1995) Neoadjuvant chemotherapy for locally advanced urothelial cancer of the upper urinary tract. Urol Int 55:74–77PubMedCrossRef
4.
Zurück zum Zitat Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP Jr, Raghavan D, Crawford ED (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 28(349):859–866CrossRef Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP Jr, Raghavan D, Crawford ED (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 28(349):859–866CrossRef
5.
Zurück zum Zitat Margulis V, Youssef RF, Karakiewicz PI, Lotan Y, Wood CG, Zigeuner R, Kikuchi E, Weizer A, Raman JD, Remzi M, Roscigno M, Montorsi F, Bolenz C, Kassouf W, Shariat SF, Upper Tract Urothelial Carcinoma Collaborative Group (2010) Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. J Urol 184:453–458PubMedCrossRef Margulis V, Youssef RF, Karakiewicz PI, Lotan Y, Wood CG, Zigeuner R, Kikuchi E, Weizer A, Raman JD, Remzi M, Roscigno M, Montorsi F, Bolenz C, Kassouf W, Shariat SF, Upper Tract Urothelial Carcinoma Collaborative Group (2010) Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. J Urol 184:453–458PubMedCrossRef
6.
Zurück zum Zitat Favaretto RL, Shariat SF, Savage C, Godoy G, Chade DC, Kaag M, Bochner BH, Coleman J, Dalbagni G (2012) Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma. BJU Int 109:77–82PubMedCrossRef Favaretto RL, Shariat SF, Savage C, Godoy G, Chade DC, Kaag M, Bochner BH, Coleman J, Dalbagni G (2012) Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma. BJU Int 109:77–82PubMedCrossRef
7.
Zurück zum Zitat Saito K, Kihara K (2011) C-reactive protein as a biomarker for urological cancers. Nat Rev Urol 8:659–666PubMed Saito K, Kihara K (2011) C-reactive protein as a biomarker for urological cancers. Nat Rev Urol 8:659–666PubMed
8.
Zurück zum Zitat Hilmy M, Bartlett JM, Underwood MA, McMillan DC (2005) The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer 28(92):625–627CrossRef Hilmy M, Bartlett JM, Underwood MA, McMillan DC (2005) The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer 28(92):625–627CrossRef
9.
Zurück zum Zitat Gondo T, Nakashima J, Ohno Y, Choichiro O, Horiguchi Y, Namiki K, Yoshioka K, Ohori M, Hatano T, Tachibana M (2012) Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy. Urology 79:1085–1091PubMedCrossRef Gondo T, Nakashima J, Ohno Y, Choichiro O, Horiguchi Y, Namiki K, Yoshioka K, Ohori M, Hatano T, Tachibana M (2012) Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy. Urology 79:1085–1091PubMedCrossRef
10.
Zurück zum Zitat An X, Ding PR, Li YH, Wang FH, Shi YX, Wang ZQ, He YJ, Xu RH, Jiang WQ (2010) Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomakers 15:516–522CrossRef An X, Ding PR, Li YH, Wang FH, Shi YX, Wang ZQ, He YJ, Xu RH, Jiang WQ (2010) Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomakers 15:516–522CrossRef
11.
Zurück zum Zitat Azab B, Bhatt VR, Phookan S, Kohn N, Terijanian T, Widmann WD (2012) Usefullness of neutrophil-lymphocyte ratio in predicting short- and long term mortality in breast cancer patients. Ann Surg Oncol 19:217–224PubMedCrossRef Azab B, Bhatt VR, Phookan S, Kohn N, Terijanian T, Widmann WD (2012) Usefullness of neutrophil-lymphocyte ratio in predicting short- and long term mortality in breast cancer patients. Ann Surg Oncol 19:217–224PubMedCrossRef
12.
Zurück zum Zitat Ohno Y, Nakashima J, Ohori M, Hatano T, Tachibana M (2010) Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. J Urol 2184:873–878CrossRef Ohno Y, Nakashima J, Ohori M, Hatano T, Tachibana M (2010) Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. J Urol 2184:873–878CrossRef
13.
Zurück zum Zitat Kao SC, Pavlakis N, Harvie R, Vardy JL, Boyer MJ, van Zandwijk N, Clarke SJ (2010) High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 16:5805–5813PubMedCrossRef Kao SC, Pavlakis N, Harvie R, Vardy JL, Boyer MJ, van Zandwijk N, Clarke SJ (2010) High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 16:5805–5813PubMedCrossRef
14.
Zurück zum Zitat Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O’Reilly DS, Foulis AK, Horgan PG, McMillan DC (2011) A comparison of inflammation-based prognostic scores in patients with cancer. A glasgow inflammation outcome study. Eur J Cancer 47:2633–2641PubMedCrossRef Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O’Reilly DS, Foulis AK, Horgan PG, McMillan DC (2011) A comparison of inflammation-based prognostic scores in patients with cancer. A glasgow inflammation outcome study. Eur J Cancer 47:2633–2641PubMedCrossRef
15.
Zurück zum Zitat Donskov F, von der Maase H (2006) Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 24:1997–2005PubMedCrossRef Donskov F, von der Maase H (2006) Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 24:1997–2005PubMedCrossRef
16.
Zurück zum Zitat Schmidt H, Suciu S, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, von der Maase H, Eggermont AM, Keilholz U, American Joint Committee on Cancer Stage IV Melanoma, EORTC 18951 (2007) Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. J Clin Oncol 20(25):1562–1569CrossRef Schmidt H, Suciu S, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, von der Maase H, Eggermont AM, Keilholz U, American Joint Committee on Cancer Stage IV Melanoma, EORTC 18951 (2007) Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. J Clin Oncol 20(25):1562–1569CrossRef
17.
Zurück zum Zitat Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K, Komuta K, Minato K, Mio T, Fujita Y, Yonei T, Nakano K, Tsuboi M, Shibata K, Furuse K, Fukushima M (2009) Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer 45:1950–1958PubMedCrossRef Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K, Komuta K, Minato K, Mio T, Fujita Y, Yonei T, Nakano K, Tsuboi M, Shibata K, Furuse K, Fukushima M (2009) Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer 45:1950–1958PubMedCrossRef
18.
Zurück zum Zitat Sobin LH, Wittekind C (2002) TNM classification of malignant tumors, 6th edn. Wiley-Liss Inc, New York Sobin LH, Wittekind C (2002) TNM classification of malignant tumors, 6th edn. Wiley-Liss Inc, New York
19.
Zurück zum Zitat Atzpodien J, Royston P, Wandert T, Reitz M, DGCIN—German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group (2003) Metastatic renal cell carcinoma comprehensive prognostic system. Br J Cancer 88:348–353PubMedCrossRef Atzpodien J, Royston P, Wandert T, Reitz M, DGCIN—German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group (2003) Metastatic renal cell carcinoma comprehensive prognostic system. Br J Cancer 88:348–353PubMedCrossRef
20.
Zurück zum Zitat Tazzyman S, Lewis CE, Murdoch C (2009) Neutrophils: key mediators of tumour angiogenesis. Int J Exp Pathol 90:222–231PubMedCrossRef Tazzyman S, Lewis CE, Murdoch C (2009) Neutrophils: key mediators of tumour angiogenesis. Int J Exp Pathol 90:222–231PubMedCrossRef
21.
Zurück zum Zitat Tachibana M, Miyakawa A, Tazaki H, Nakamura K, Kubo A, Hata J, Nishi T, Amano Y (1995) Autocrine growth of transitional cell carcinoma of the bladder induced by granulocyte-colony stimulating factor. Cancer Res 1(55):3438–3443 Tachibana M, Miyakawa A, Tazaki H, Nakamura K, Kubo A, Hata J, Nishi T, Amano Y (1995) Autocrine growth of transitional cell carcinoma of the bladder induced by granulocyte-colony stimulating factor. Cancer Res 1(55):3438–3443
22.
Zurück zum Zitat Okamoto M, Hattori K, Oyasu R (1997) Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro. Int J Cancer 72:149–154PubMedCrossRef Okamoto M, Hattori K, Oyasu R (1997) Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro. Int J Cancer 72:149–154PubMedCrossRef
23.
Zurück zum Zitat Andrews B, Shariat SF, Kim JH, Wheeler TM, Slawin KM, Lerner SP (2002) Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. J Urol 167:1475–1481PubMedCrossRef Andrews B, Shariat SF, Kim JH, Wheeler TM, Slawin KM, Lerner SP (2002) Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. J Urol 167:1475–1481PubMedCrossRef
24.
Zurück zum Zitat Hellenthal NJ, Shariat SF, Margulis V, Karakiewicz PI, Roscigno M, Bolenz C, Remzi M, Weizer A, Zigeuner R, Bensalah K, Ng CK, Raman JD, Kikuchi E, Montorsi F, Oya M, Wood CG, Fernandez M, Evans CP, Koppie TM (2009) Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. J Urol 182:900–906PubMedCrossRef Hellenthal NJ, Shariat SF, Margulis V, Karakiewicz PI, Roscigno M, Bolenz C, Remzi M, Weizer A, Zigeuner R, Bensalah K, Ng CK, Raman JD, Kikuchi E, Montorsi F, Oya M, Wood CG, Fernandez M, Evans CP, Koppie TM (2009) Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. J Urol 182:900–906PubMedCrossRef
25.
Zurück zum Zitat Kaag MG, O’Malley RL, O’Malley P, Godoy G, Chen M, Smaldone MC, Hrebinko RL, Raman JD, Bochner B, Dalbagni G, Stifelman MD, Taneja SS, Huang WC (2010) Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol 58:581–587PubMedCrossRef Kaag MG, O’Malley RL, O’Malley P, Godoy G, Chen M, Smaldone MC, Hrebinko RL, Raman JD, Bochner B, Dalbagni G, Stifelman MD, Taneja SS, Huang WC (2010) Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol 58:581–587PubMedCrossRef
26.
Zurück zum Zitat Lehmann J, Suttmann H, Kovac I, Hack M, Kamradt J, Siemer S, Wullich B, Zwergel U, Stöckle M (2007) Transitional cell carcinoma of the ureter: prognostic factors influencing progression and survival. Eur Urol 51:1281–1288PubMedCrossRef Lehmann J, Suttmann H, Kovac I, Hack M, Kamradt J, Siemer S, Wullich B, Zwergel U, Stöckle M (2007) Transitional cell carcinoma of the ureter: prognostic factors influencing progression and survival. Eur Urol 51:1281–1288PubMedCrossRef
27.
Zurück zum Zitat Fritz GA, Schoellnast H, Deutschmann HA, Quehenberger F, Tillich M (2006) Multiphasic multidetector-row CT (MDCT) in detection and staging of transitional cell carcinomas of the upper urinary tract. Eur Radiol 16:1244–1252PubMedCrossRef Fritz GA, Schoellnast H, Deutschmann HA, Quehenberger F, Tillich M (2006) Multiphasic multidetector-row CT (MDCT) in detection and staging of transitional cell carcinomas of the upper urinary tract. Eur Radiol 16:1244–1252PubMedCrossRef
28.
Zurück zum Zitat Negru D, Negru I, Pricop C, Novac C, Daniil C (2002) Transitional cell carcinoma of the upper urinary tract- staging by computed tomography. Rev Med Chir Soc Med Nat Iasi 106:736–740PubMed Negru D, Negru I, Pricop C, Novac C, Daniil C (2002) Transitional cell carcinoma of the upper urinary tract- staging by computed tomography. Rev Med Chir Soc Med Nat Iasi 106:736–740PubMed
Metadaten
Titel
Clinical significance of preoperative peripheral blood neutrophil count in patients with non-metastatic upper urinary tract carcinoma
verfasst von
Takeshi Hashimoto
Yoshio Ohno
Jun Nakashima
Tatsuo Gondo
Makoto Ohori
Masaaki Tachibana
Publikationsdatum
01.08.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 4/2013
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-012-0942-x

Weitere Artikel der Ausgabe 4/2013

World Journal of Urology 4/2013 Zur Ausgabe

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.